We catch up with the latest twists and turns in national and international cannabis regulation
Charlotte Barker | | Quick Read
Epidiolex descheduled. For the first time, a cannabinoid medicine (Epidiolex, a CBD-based therapy used to treat Dravet syndrome) has been descheduled by the US DEA. Read the press release from manufacturer GW Pharma here.
EVALI leads to tighter cannabis controls. Oregon officials will carry out random testing for unlicensed additives in cannabis products and Washington State passed an emergency rule banning vape products containing vitamin E acetate. A second rule “requires manufacturers of THC products to disclose all compounds (including ingredients, solvents, additives, etc.) used in the production and processing as well as the sources of all vapor products."
Read the full article now
Log in or register to read this article in full and gain access to The Cannabis Scientist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Cannabis Scientist magazine